Nurix Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Nurix Therapeutics (Nasdaq: NRIX) has announced that its CEO, Arthur T. Sands, M.D., Ph.D., will participate in two upcoming virtual healthcare conferences in November. The events include the Stifel 2021 Virtual Healthcare Conference on November 16, from 3:20 to 3:50 PM EST, and the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 30, from 11:30 to 11:55 AM EST. These discussions will be available via live webcast through the Investors section of the Nurix website, with archived copies accessible for 30 days following each event.

SAN FRANCISCO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in fireside chats at the following conferences in November:

• Stifel 2021 Virtual Healthcare Conference
  Tuesday, November 16^th, at 3:20-3:50 PM EST
  
• Piper Sandler 33rd Annual Virtual Healthcare Conference
  Tuesday, November 30^th, at 11:30-11:55 AM EST

The discussions will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. Archived copies of the webcasts will be available on the Nurix website for approximately 30 days after the event.

About Nurix Therapeutics, Inc.
Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For more information, please visit http://www.nurix.com.

Contacts:

Investors:	Media:
Jason Kantor, Ph.D.	Elizabeth Wolffe, Ph.D.
Nurix Therapeutics, Inc.	Wheelhouse Life Science Advisors
jkantor@nurixtx.com	lwolffe@wheelhouselsa.com

FAQ

When is the Stifel 2021 Virtual Healthcare Conference for NRIX?

The Stifel 2021 Virtual Healthcare Conference for Nurix Therapeutics (NRIX) is scheduled for November 16, 2021, from 3:20 to 3:50 PM EST.

What is the date and time for the Piper Sandler Conference for NRIX?

The Piper Sandler 33rd Annual Virtual Healthcare Conference for Nurix Therapeutics (NRIX) will take place on November 30, 2021, from 11:30 to 11:55 AM EST.

How can I access the webcasts of NRIX's conference presentations?

The webcasts of Nurix Therapeutics' conference presentations can be accessed live through the Investors section of the Nurix website, with archived versions available for 30 days after the events.

Who will represent Nurix Therapeutics at the November conferences?

Arthur T. Sands, M.D., Ph.D., the president and CEO of Nurix Therapeutics, will represent the company at the upcoming November conferences.